Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Trading Down 19.2 %

PULM opened at $5.43 on Monday. The stock has a market capitalization of $19.82 million, a PE ratio of -2.06 and a beta of 0.99. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $8.44. The firm has a 50-day moving average price of $2.41 and a two-hundred day moving average price of $2.16.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.